<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>IPRATROPIUM BROMIDE- ipratropium bromide solution </strong><br>Aidarex Pharmaceuticals LLC<br></p></div>
<h1>IPRATROPIUM BROMIDE INHALATION SOLUTION, 0.02%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ed8ad498-4800-4bdf-b230-c529fa1b885b"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Prescribing Information</span></p>
<p><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_83aa7df7-799f-4852-8b26-c5df9b788dca"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">The active ingredient, ipratropium bromide monohydrate, USP, is an anticholinergic bronchodilator chemically described as 8-azoniabicyclo [3.2.1]- octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, monohydrate (endo, syn)-, (±)-; a synthetic quaternary ammonium compound, chemically related to atropine.</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=769febba-671d-476b-b0c8-71489a2f9d20&amp;name=ipratropium-inh-for-ritedose-1.jpg"></div>
<p>Ipratropium Bromide Monohydrate  C<span class="Sub">20</span>H<span class="Sub">30</span>BrNO<span class="Sub">3</span>•H<span class="Sub">2</span>O  Mol.Wt. 430.4</p>
<p>Ipratropium bromide is a white crystalline substance, freely soluble in water and lower alcohols. It is a quaternary ammonium compound and thus exists in an ionized state in aqueous solutions. It is relatively insoluble in non-polar media.</p>
<p>Ipratropium Bromide Inhalation Solution is administered by oral inhalation with the aid of a nebulizer. It contains ipratropium bromide, USP 0.02% (anhydrous basis) in a sterile, preservative-free, isotonic saline solution, pH-adjusted to 3.4 (3 to 4) with hydrochloric acid.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_8131aac1-14d8-403d-81fa-95c1668b1fe6"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Ipratropium bromide is an anticholinergic (parasympatholytic) agent that, based on animal studies, appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve.</p>
<p>Anticholinergics prevent the increases in intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) that are caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle.</p>
<p>The bronchodilation following inhalation of ipratropium bromide is primarily a local, site-specific effect, not a systemic one. Much of an administered dose is swallowed but not absorbed, as shown by fecal excretion studies. Following nebulization of a 2 mg dose, a mean 7% of the dose was absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract. The half-life of elimination is about 1.6 hours after intravenous administration. Ipratropium bromide is minimally (0 to 9% <span class="Italics">in vitro</span>) bound to plasma albumin and a<span class="Sub">1</span>-acid glycoproteins. It is partially metabolized. Autoradiographic studies in rats have shown that ipratropium bromide does not penetrate the blood-brain barrier. Ipratropium bromide has not been studied in patients with hepatic or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. It should be used with caution in those patient populations.</p>
<p>In controlled 12-week studies in patients with <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> associated with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> and <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>) significant improvements in pulmonary function (FEV<span class="Sub">1</span> increases of 15% or more) occurred within 15 to 30 minutes, reached a peak in 1 to 2 hours, and persisted for periods of 4 to 5 hours in the majority of patients, with about 25% to 38% of the patients demonstrating increases of 15% or more for at least 7 to 8 hours. Continued effectiveness of ipratropium bromide inhalation solution was demonstrated throughout the 12-week period. In addition, significant increases in forced <span class="product-label-link" type="condition" conceptid="4147814" conceptname="Vital capacity">vital capacity</span> (FVC) have been demonstrated. However, ipratropium bromide did not consistently produce significant improvement in subjective symptom scores nor in quality of life scores over the 12-week duration of study.</p>
<p>Additional controlled 12-week studies were conducted to evaluate the safety and effectiveness of ipratropium bromide inhalation solution administered concomitantly with the beta adrenergic bronchodilator solutions metaproterenol and albuterol compared with the administration of each of the beta agonists alone. Combined therapy produced significant additional improvement in FEV<span class="Sub">1</span> and FVC. On combined therapy, the median duration of 15% improvement in FEV<span class="Sub">1</span> was 5 to 7 hours, compared with 3 to 4 hours in patients receiving a beta agonist alone.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_bc97034b-9681-4d20-a832-521e1ba83af1"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> associated with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, including <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span> and <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_ddcdbcf0-2f87-4744-af0d-0153e0d21088"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Ipratropium bromide is contraindicated in known or suspected cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ipratropium bromide, or to atropine and its derivatives.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_c5e5b834-1307-4df1-b540-91a1c0790eef"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">The use of ipratropium bromide inhalation solution as a single agent for the relief of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in acute <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbation</span> has not been adequately studied. Drugs with faster onset of action may be preferable as initial therapy in this situation. Combination of ipratropium bromide and beta agonists has not been shown to be more effective than either drug alone in reversing the <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> associated with acute <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD exacerbation</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate hypersensitivity reactions</span> may occur after administration of ipratropium bromide, as demonstrated by rare cases of <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> and oropharyngeal <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_7f97ff85-3053-43b8-a831-3188ef60980a"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_08becc8b-784a-4715-bd8f-638667305a28"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Ipratropium bromide should be used with caution in patients with narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or bladder-neck obstruction.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_3990dfe6-d4ca-4c52-a129-e18ac177489c"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be advised that temporary <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span>, precipitation or worsening of narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> may result if the solution comes into direct contact with the eyes. Use of a nebulizer with mouthpiece rather than face mask may be preferable, to reduce the likelihood of the nebulizer solution reaching the eyes. Patients should be advised that ipratropium bromide inhalation solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour. Drug stability and safety of Ipratropium Bromide Inhalation Solution when mixed with other drugs in a nebulizer have not been established. Patients should be reminded that ipratropium bromide inhalation solution should be used consistently as prescribed throughout the course of therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_c70f39be-c019-473d-9b91-4e0e36209643"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Ipratropium bromide has been shown to be a safe and effective bronchodilator when used in conjunction with beta adrenergic bronchodilators. Ipratropium bromide has also been used with other pulmonary medications, including methylxanthines and corticosteroids, without adverse drug interactions.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_40bec7bf-1f93-464f-a315-0c8c00cefc9d"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Two-year oral carcinogenicity studies in rats and mice have revealed no carcinogenic potential at dietary doses up to 6 mg/kg/day of ipratropium bromide.</p>
<p>Results of various mutagenicity studies (Ames test, mouse dominant lethal test, mouse micronucleus test and chromosome aberration of bone marrow in Chinese hamsters) were negative.</p>
<p>Fertility of male or female rats at oral doses up to 50 mg/kg/day was unaffected by ipratropium bromide administration. At doses above 90 mg/kg increased resorption and decreased conception rates were observed.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_4909b722-5452-42db-9add-f1606dad76b2"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_f4c7f6ae-b499-414d-8475-5c7ea7075f70"></a><a name="section-7.5.1"></a><p></p>
<h3>TERATOGENIC EFFECTS</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6d60ae6a-8855-4118-a2d1-24461e7c3bf5"></a><a name="section-7.5.1.1"></a><p></p>
<h4>Pregnancy Category B</h4>
<p class="First">Oral reproduction studies performed in mice, rats and rabbits at doses of 10, 100, and 125 mg/kg respectively, and inhalation reproduction studies in rats and rabbits at doses of 1.5 and 1.8 mg/kg (or approximately 38 and 45 times the recommended human daily dose) respectively, have demonstrated no evidence of teratogenic effects as a result of ipratropium bromide. However, no adequate or well-controlled studies have been conducted in pregnant women. Because animal reproduction studies are not always predictive of human response, ipratropium bromide should be used during pregnancy only if clearly needed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_8e63eeff-c5aa-427f-a02c-071a1e9ad514"></a><a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether ipratropium bromide is excreted in human milk. Although lipid-insoluble quaternary bases pass into breast milk, it is unlikely that ipratropium bromide would reach the infant to a significant extent, especially when taken by inhalation since ipratropium bromide is not well absorbed systemically after inhalation or oral administration. However, because many drugs are excreted in human milk, caution should be exercised when ipratropium bromide is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_30866d71-644c-4f18-a72d-548c6a7065fe"></a><a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in the pediatric population below the age of 12 have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_30067141-8d38-4c9f-b206-b33cc1b5d502"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reaction information concerning ipratropium bromide inhalation solution is derived from 12-week active-controlled clinical trials. Additional information is derived from foreign post-marketing experience and the published literature.</p>
<p>All adverse events, regardless of drug relationship, reported by three percent or more patients in the 12-week controlled clinical trials appear in the table below.</p>
<p>Additional adverse reactions reported in less than three percent of the patients treated with ipratropium bromide include <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. Cases of precipitation or worsening of narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, and acute <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> have been reported.</p>
<p>Lower respiratory adverse reactions (<span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>) were the most common events leading to discontinuation of ipratropium bromide therapy in the 12-week trials. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, mouth dryness and aggravation of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> symptoms are more common when the total daily dose of ipratropium bromide equals or exceeds 2,000 mcg.</p>
<p>Allergic-type reactions such as skin-<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> of tongue, lips and face, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> have been reported. Many of the patients had a history of allergies to other drugs and/or foods.</p>
<table>
<caption><span>All Adverse Events, from a Double-blind, Parallel, 12-week Study of patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<thead>
<tr class="First">
<th valign="top"></th>
<th align="center" colspan="5" valign="top"> PERCENT OF PATIENTS</th>
</tr>
<tr>
<th valign="bottom"></th>
<th align="center" valign="bottom"><span class="Underline">Ipratropium</span></th>
<th align="center" valign="bottom"><span class="Underline">Metaproterenol</span></th>
<th align="center" valign="bottom"><span class="Underline">Ipratropium/<br>Metaproterenol</span></th>
<th align="center" valign="bottom"><span class="Underline">Albuterol</span></th>
<th align="center" valign="bottom"><span class="Underline">Ipratropium/<br>Albuterol</span></th>
</tr>
<tr>
<th valign="top"></th>
<th align="center" valign="top"> (500 mcg t.i.d.)</th>
<th align="center" valign="top"> (15 mg t.i.d.)</th>
<th align="center" valign="top"> (500 mcg t.i.d./<br>15 mg t.i.d.)</th>
<th align="center" valign="top"> (2.5 mg t.i.d.)</th>
<th align="center" valign="top"> (500 mcg t.i.d./<br>2.5 mg t.i.d.)</th>
</tr>
<tr class="Last">
<th valign="top"></th>
<th align="center" valign="top"> n = 219</th>
<th align="center" valign="top"> n = 212</th>
<th align="center" valign="top"> n = 108</th>
<th align="center" valign="top"> n = 205</th>
<th align="center" valign="top"> n = 100</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>All adverse events, regardless of drug relationship, reported by three percent or more patients in the 12-week controlled clinical trials.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td valign="top"> <span class="Underline">Body as a Whole-General Disorders</span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top"> 6.4</td>
<td align="center" valign="top"> 5.2</td>
<td align="center" valign="top"> 6.5</td>
<td align="center" valign="top"> 6.3</td>
<td align="center" valign="top"> 9.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="center" valign="top"> 4.1</td>
<td align="center" valign="top"> 3.3</td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 2.9</td>
<td align="center" valign="top"> 5.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td align="center" valign="top"> 3.7</td>
<td align="center" valign="top"> 4.7</td>
<td align="center" valign="top"> 6.5</td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> 1.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="center" valign="top"> 3.2</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 2.4</td>
<td align="center" valign="top"> 0.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td align="center" valign="top"> 3.2</td>
<td align="center" valign="top"> 4.2</td>
<td align="center" valign="top"> 5.6</td>
<td align="center" valign="top"> 2.0</td>
<td align="center" valign="top"> 1.0</td>
</tr>
<tr>
<td valign="top"> <span class="Underline"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>/<span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Hypertension Aggravated</span></td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 1.5</td>
<td align="center" valign="top"> 4.0</td>
</tr>
<tr>
<td valign="top"> <span class="Underline">Central &amp; Peripheral Nervous System</span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top"> 2.3</td>
<td align="center" valign="top"> 3.3</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 3.9</td>
<td align="center" valign="top"> 4.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> 4.6</td>
<td align="center" valign="top"> 1.0</td>
<td align="center" valign="top"> 1.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 7.1</td>
<td align="center" valign="top"> 8.3</td>
<td align="center" valign="top"> 1.0</td>
<td align="center" valign="top"> 0.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> 4.7</td>
<td align="center" valign="top"> 6.5</td>
<td align="center" valign="top"> 1.0</td>
<td align="center" valign="top"> 1.0</td>
</tr>
<tr>
<td valign="top"> <span class="Underline">Gastrointestinal System Disorders</span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> Mouth Dryness</td>
<td align="center" valign="top"> 3.2</td>
<td align="center" valign="top"> 0.0</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 2.0</td>
<td align="center" valign="top"> 3.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top"> 4.1</td>
<td align="center" valign="top"> 3.8</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 2.9</td>
<td align="center" valign="top"> 2.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 0.0</td>
<td align="center" valign="top"> 3.7</td>
<td align="center" valign="top"> 1.0</td>
<td align="center" valign="top"> 1.0</td>
</tr>
<tr>
<td valign="top"> <span class="Underline">Musculo-skeletal System Disorders</span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 1.4</td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 0.5</td>
<td align="center" valign="top"> 3.0</td>
</tr>
<tr>
<td valign="top"> <span class="Underline"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span> (Lower)</span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td align="center" valign="top"> 4.6</td>
<td align="center" valign="top"> 8.0</td>
<td align="center" valign="top"> 6.5</td>
<td align="center" valign="top"> 5.4</td>
<td align="center" valign="top"> 6.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center" valign="top"> 9.6</td>
<td align="center" valign="top"> 13.2</td>
<td align="center" valign="top"> 16.7</td>
<td align="center" valign="top"> 12.7</td>
<td align="center" valign="top"> 9.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td align="center" valign="top"> 14.6</td>
<td align="center" valign="top"> 24.5</td>
<td align="center" valign="top"> 15.7</td>
<td align="center" valign="top"> 16.6</td>
<td align="center" valign="top"> 20.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span></td>
<td align="center" valign="top"> 2.3</td>
<td align="center" valign="top"> 2.8</td>
<td align="center" valign="top"> 4.6</td>
<td align="center" valign="top"> 5.4</td>
<td align="center" valign="top"> 5.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">Sputum</span> Increased</td>
<td align="center" valign="top"> 1.4</td>
<td align="center" valign="top"> 1.4</td>
<td align="center" valign="top"> 4.6</td>
<td align="center" valign="top"> 3.4</td>
<td align="center" valign="top"> 0.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory Disorder</span></td>
<td align="center" valign="top"> 0.0</td>
<td align="center" valign="top"> 6.1</td>
<td align="center" valign="top"> 6.5</td>
<td align="center" valign="top"> 2.0</td>
<td align="center" valign="top"> 4.0</td>
</tr>
<tr>
<td valign="top"> <span class="Underline"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span> (Upper)</span>
</td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
<td align="center" valign="top"> </td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></td>
<td align="center" valign="top"> 13.2</td>
<td align="center" valign="top"> 11.3</td>
<td align="center" valign="top"> 9.3</td>
<td align="center" valign="top"> 12.2</td>
<td align="center" valign="top"> 16.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td align="center" valign="top"> 3.7</td>
<td align="center" valign="top"> 4.2</td>
<td align="center" valign="top"> 5.6</td>
<td align="center" valign="top"> 2.9</td>
<td align="center" valign="top"> 4.0</td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center" valign="top"> 2.3</td>
<td align="center" valign="top"> 4.2</td>
<td align="center" valign="top"> 1.9</td>
<td align="center" valign="top"> 2.4</td>
<td align="center" valign="top"> 0.0</td>
</tr>
<tr class="Last">
<td valign="top"> Sinusitus</td>
<td align="center" valign="top"> 2.3</td>
<td align="center" valign="top"> 2.8</td>
<td align="center" valign="top"> 0.9</td>
<td align="center" valign="top"> 5.4</td>
<td align="center" valign="top"> 4.0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_ece0cb0d-a1af-43d0-9027-815a5ea029b0"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Acute systemic overdosage by inhalation solution is unlikely since ipratropium bromide is not well absorbed after inhalation at up to four-fold the recommended dose, or after oral administration at up to forty-fold the recommended dose. The oral LD<span class="Sub">50</span> of ipratropium bromide ranged between 1001 and 2010 mg/kg in mice; between 1667 and 4000 mg/kg in rats; and between 400 and 1300 mg/kg in dogs.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_70fc8216-dfd1-484f-bdef-a23a00e91009"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual dosage of ipratropium bromide inhalation solution is 500 mcg (1 Unit-Dose Vial) administered three to four times a day by oral nebulization, with doses 6 to 8 hours apart. Ipratropium bromide inhalation solution unit-dose vials contain 500 mcg ipratropium bromide, USP anhydrous in 2.5 mL normal saline. Ipratropium bromide inhalation solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour. Drug stability and safety of Ipratropium Bromide Inhalation Solution when mixed with other drugs in a nebulizer have not been established.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_50afe134-a4b6-49ae-9fee-e389cecc2ff9"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Ipratropium Bromide Inhalation Solution Unit Dose Vial is supplied as a 0.02% clear, colorless solution containing 2.5 mL.</p>
<p>NDC 53217-0008-01, 60 vials per carton / 30 vials per foil pouch</p>
<p>Each vial is made from a low density polyethylene (LDPE) resin.</p>
<p>Vials are supplied in a foil pouch.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_91353d6e-0df8-41ce-86bb-111dfac9ec73"></a><a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Store between 59°F (15°C) and 86°F (30°C).</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Store unused vials in the foil pouch.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8da15c02-b627-492d-995d-2aae639cc1a9"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">ATTENTION PHARMACIST: Detach "Patient's Instructions for Use" from Package Insert and dispense with solution.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Manufactured by:</span><br>The Ritedose Corporation<br>Columbia, SC 29203 for <br>Ritedose Pharmaceuticals, LLC<br>Columbia, SC 29203</p>
<p><span class="Bold">To report SUSPECTED ADVERSE<br>REACTIONS, contact Ritedose<br>Pharmaceuticals, LLC <br>at 1-855-806-3300 or FDA<br>at 1-800-FDA-1088 or<span class="Italics"><a href="#medwatch">www.fda.gov/medwatch</a></span></span></p>
<p>Repackaged By :<br>Aidarex Pharmaceuticals LLC,<br>Corona, CA 92880</p>
<p>RPIN0044<br>JAN 2013</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="LINK_6aa83a0a-a139-408c-8076-fe70414aff1c"></a><a name="section-13"></a><p></p>
<h1>Patient's Instructions for Use</h1>
<p class="First"><span class="Bold">Ipratropium Bromide</span></p>
<p><span class="Bold">Inhalation Solution 0.02%</span></p>
<p>Read complete instructions carefully before using.</p>
<ul class="Disk">
<li>1.Twist   open the top of one unit dose vial and squeeze the contents into the   nebulizer reservoir. (Figure 1).<br><div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=769febba-671d-476b-b0c8-71489a2f9d20&amp;name=ipratropium-inh-for-ritedose-2.jpg"></div>
</li>
<li>2.Connect   the nebulizer reservoir to the mouthpiece or face mask (Figure 2).<br><div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=769febba-671d-476b-b0c8-71489a2f9d20&amp;name=ipratropium-inh-for-ritedose-3.jpg"></div>
</li>
<li>3.Connect   the nebulizer to the compressor.</li>
<li>4.Sit   in a comfortable, upright position; place the mouthpiece in your mouth   (Figure 3) or put on the face mask and turn on the compressor. If a face   mask is used, care should be taken to avoid leakage around the mask as   temporary <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span>, pupil enlargement, precipitation or worsening of narrow angle   <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> may occur if the solution comes into direct contact   with the eyes.<br><div class="Figure"><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=769febba-671d-476b-b0c8-71489a2f9d20&amp;name=ipratropium-inh-for-ritedose-4.jpg"></div>
</li>
<li>5.<span class="Bold">Breathe   as calmly, deeply, and evenly</span> as possible until no   more mist is formed in the nebulizer chamber (about 5 to 15 minutes). At   this point, the treatment is finished.</li>
<li>6.Clean   the nebulizer (see manufacturer's instructions).</li>
</ul>
<p><span class="Bold">Note: Use only as directed by your physician. More frequent administration or higher doses are not recommended. Ipratropium Bromide Inhalation Solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour but not with other drugs. Drug stability and safety of Ipratropium Bromide Inhalation Solution when mixed with other drugs in the nebulizer have not been established.</span></p>
<p><span class="Bold">Store between 59°F (15°C) and 86°F (30°). Protect from light. Store unused vials in the foil pouch.</span></p>
<p><span class="Bold">ADDITIONAL INSTRUCTIONS:<br> ____________________________________<br> ____________________________________ <br>____________________________________ <br>____________________________________ <br>____________________________________ <br>____________________________________ <br>____________________________________</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_abd7c937-9892-4cab-a63c-9a7a8597e4f0"></a><a name="section-14"></a><p></p>
<h1></h1>
<p class="First">Manufactured by: <br>The Ritedose Corporation<br>Columbia, SC 29203 for <br>Ritedose Pharmaceuticals, LLC<br>Columbia, SC 29203</p>
<p><span class="Bold">To report SUSPECTED ADVERSE<br>REACTIONS, contact Ritedose<br>Pharmaceuticals, LLC <br>at 1-855-806-3300 or FDA<br>at 1-800-FDA-1088 or<span class="Italics"><a href="#medwatch">www.fda.gov/medwatch</a></span></span></p>
<p>Repackaged By :<br>Aidarex Pharmaceuticals LLC,<br>Corona, CA 92880</p>
<p>JAN 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_b9b220a8-291e-4c54-ad14-dd3d89e4722f"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 60 Ampule Carton</h1>
<p class="First">NDC 53217-0008-01</p>
<p><span class="Bold">Ipratropium Bromide<br>Inhalation Solution, 0.02%</span></p>
<p>0.5 mg / 2.5 mL</p>
<p><span class="Bold">FOR ORAL INHALATION ONLY</span></p>
<p><span class="Bold">INGREDIENTS:</span> Each low density polyethylene vial contains: 2.5 mL Ipratropium Bromide 0.02%,<br>preservative free, isotonic sterile aqueous solution containing sodium chloride. Adjusted to pH 3.4 (3 to 4)<br>with hydrochloric acid.</p>
<p><span class="Bold">Usual Dosage:</span> See accompanying prescribing information.</p>
<p><span class="Bold">Store between 15° and 30°C (59° and 86°F). Protect from light. Store unused vials in the foil pouch.</span></p>
<p><span class="Bold">ATTENTION PHARMACIST:</span> Detach "Patient's Instructions For Use" from package insert and<br>dispense with solution.</p>
<p><span class="Bold">Rx Only</span></p>
<div class="Figure"><img alt="IMAGE LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=769febba-671d-476b-b0c8-71489a2f9d20&amp;name=ipratropium-inh-for-ritedose-5.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>IPRATROPIUM BROMIDE 		
					</strong><br><span class="contentTableReg">ipratropium bromide solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53217-008(NDC:76204-100)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>IPRATROPIUM BROMIDE</strong> (IPRATROPIUM) </td>
<td class="formItem">IPRATROPIUM BROMIDE ANHYDROUS</td>
<td class="formItem">0.5 mg  in 2.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53217-008-01</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 AMPULE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075693</td>
<td class="formItem">02/01/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Aidarex Pharmaceuticals LLC
							(801503249)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3a79526b-bcfe-4635-82a6-73cafe9b13eb</div>
<div>Set id: 769febba-671d-476b-b0c8-71489a2f9d20</div>
<div>Version: 1</div>
<div>Effective Time: 20131006</div>
</div>
</div> <div class="DistributorName">Aidarex Pharmaceuticals LLC</div></p>
</body></html>
